Cytek Biosciences, Inc.
CTKB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $99 | $167 | $297 | $365 |
| Short-Term Investments | $179 | $95 | $45 | $0 |
| Receivables | $61 | $56 | $51 | $30 |
| Inventory | $44 | $61 | $48 | $32 |
| Other Curr. Assets | $14 | $13 | $14 | $5 |
| Total Curr. Assets | $396 | $392 | $454 | $432 |
| Property Plant & Equip (Net) | $28 | $29 | $28 | $6 |
| Goodwill | $17 | $16 | $10 | $10 |
| Intangibles | $20 | $23 | $4 | $5 |
| Long-Term Investments | $2 | $2 | $0 | $0 |
| Tax Assets | $33 | $30 | $20 | $9 |
| Other NC Assets | $3 | $2 | $3 | $2 |
| Total NC Assets | $103 | $102 | $65 | $32 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $500 | $494 | $519 | $463 |
| Liabilities | – | – | – | – |
| Payables | $6 | $3 | $5 | $3 |
| Short-Term Debt | $8 | $3 | $4 | $0 |
| Tax Payable | $4 | $1 | $2 | $4 |
| Deferred Revenue | $27 | $23 | $15 | $8 |
| Other Curr. Liab. | $24 | $26 | $25 | $18 |
| Total Curr. Liab. | $68 | $56 | $49 | $33 |
| LT Debt | $9 | $11 | $15 | $0 |
| Deferred Rev, NC | $16 | $15 | $13 | $10 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $11 | $19 | $17 | $15 |
| Total NC Liab. | $36 | $45 | $45 | $25 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $11 | $12 | $15 | $0 |
| Total Liabilities | $104 | $101 | $94 | $58 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$35 | -$29 | -$17 | -$20 |
| AOCI | $0 | -$1 | -$1 | $1 |
| Other Equity | $431 | $423 | $443 | $424 |
| Total Equity | $396 | $393 | $425 | $405 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $500 | $494 | $519 | $463 |
| Net Debt | -$82 | -$153 | -$279 | -$365 |